{"id":1020576,"date":"2026-11-12T16:05:04","date_gmt":"2026-11-12T21:05:04","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/black-diamond-therapeutics-to-participate-in-upcoming-investor-conferences-5\/"},"modified":"2026-11-12T16:05:04","modified_gmt":"2026-11-12T21:05:04","slug":"black-diamond-therapeutics-to-participate-in-upcoming-investor-conferences-5","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/black-diamond-therapeutics-to-participate-in-upcoming-investor-conferences-5\/","title":{"rendered":"Black Diamond Therapeutics to Participate in Upcoming Investor Conferences"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">CAMBRIDGE, Mass., Nov.  12, 2026  (GLOBE NEWSWIRE) &#8212; <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=c2xWVRhVHrI_LUFhwxzsrFV4WCin85PebUy3zbI-HMrqA5pQGymP0wqf4kn4Tt04sQndwBfxBKWr28DUvWorQ_vcY-2qlsgxlx0-kHMcX2E=\" rel=\"nofollow\" target=\"_blank\">Black Diamond Therapeutics, Inc.<\/a> (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, including silevertinib, a potential best-in-class brain-penetrant epidermal growth factor receptor (EGFR) inhibitor, today announced its participation in upcoming investor conferences. Presentation details with President and Chief Executive Officer, Mark Velleca, M.D., Ph.D., are as follows:<\/p>\n<ul type=\"disc\">\n<li style=\"margin-top:6pt\">Jefferies Global Healthcare Conference in London presentation at 8:30am GMT \/ 3:30am ET on Thursday, November 19, 2026<\/li>\n<li style=\"margin-top:6pt\">9th Annual Evercore ISI Healthcare Conference presentation at 10:25am ET on Tuesday, December 1, 2026<\/li>\n<li style=\"margin-top:6pt\">Piper Sandler 38th Annual Healthcare Conference presentation at 12:00pm ET on Wednesday, December 2, 2026\n<\/li>\n<\/ul>\n<p align=\"justify\">Webcasts will be available at the start of the presentations on the investor relations section of the Company\u2019s website, <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=ZwzHu1jzjLlO9HU00jOADyioGNNe_Xe44uIjgFCgTVNNZxoLZTa7_8JGUr1kHBhoWiBEh-g5RqqTw0DYwjOTq5zf4IdwWOfNHbQ0d_ZDhAYXS5PWxORDLm4lXxq015LO8PLGq2xCPvxCnjvCs2PHCg==\" rel=\"nofollow\" target=\"_blank\"><u>www.blackdiamondtherapeutics.com<\/u><\/a>. Replays of the presentations will also be available and archived on the site for 90 days.<\/p>\n<p align=\"justify\">\n        <strong>About Silevertinib<\/strong>\n      <\/p>\n<p align=\"justify\">Silevertinib is an investigational oral, covalent, brain-penetrant fourth-generation tyrosine kinase inhibitor (TKI) that selectively targets classical and more than 50 non-classical EGFR mutations in NSCLC. It is also designed to potently inhibit key EGFR alterations seen in GBM. To date, over 200 patients with EGFRm NSCLC or EGFR-altered GBM have been treated with silevertinib.<\/p>\n<p align=\"justify\">Based on feedback from the U.S. Food and Drug Administration (FDA) at an End-of-Phase 2 meeting in Q4 2026, the Company is planning to initiate a Phase 3 trial in Q2 2027 in 1L EGFRm NSCLC patients. The Company is also conducting a randomized Phase 2 trial of silevertinib in patients with newly diagnosed EGFRvIII-positive GBM (NCT07326566).<\/p>\n<p align=\"justify\">\n        <strong>About Black Diamond Therapeutics<\/strong>\n      <\/p>\n<p align=\"justify\">Black Diamond Therapeutics is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The Company\u2019s MasterKey therapies are designed to address a broad spectrum of genetically defined tumors, overcome resistance, minimize wild-type mediated toxicities, and be brain penetrant to treat central nervous system disease. The Company is advancing silevertinib, an investigational brain-penetrant fourth-generation EGFR MasterKey inhibitor targeting EGFR-mutant NSCLC and GBM. For more information, please visit www.blackdiamondtherapeutics.com.<\/p>\n<p align=\"justify\">\n        <strong>Contacts<\/strong>\n      <\/p>\n<p align=\"justify\">For Investors:<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=YzE7P69FC11tG6DadktQKC07k4gxgmJt4lPpoFhRZMTnbSv5KwpI4eGCcFT8RBgjW19qC8NkK9dgo0-69MySOGmk8rHQ8v-Ff_v3VUBJJ7XFZgrdW8rTszaQvhdk8tDc1Im0r7DahTLCfo7zXMWRjSvADbXKdCchiRvohJ6vqDQNp7-z_augdd7xK4x1DSUca0YA8Dy3Puw--NDvAPCIMF41wA-JxPE2azBkvZJ_gsvkWtlveZu1szTPH_80oqkWpMgkWDeaeU7NSwvTNTXnMA==\" rel=\"nofollow\" target=\"_blank\"><u>investors@bdtx.com<\/u><\/a><\/p>\n<p align=\"justify\">For Media:<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=MXbJk3XQ0hJ0aU9ASaU9f19L71t2uOI6aao8POk9Fv7PDb0QQArWb8UuSyX6Vxp3g_9P2vgqyr4MyuEHUMgxww==\" rel=\"nofollow\" target=\"_blank\"><u>media@bdtx.com<\/u><\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3NjAwMiM3OTYxNTMzIzIxOTAwNTg=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/Y2MyMmRlZDItZWZjNy00Mjk0LTg2ZDUtYmY4NTcxNTE4MTgyLTEyMDE2MTEtMjAyNi0xMS0xMi1lbg==\/tiny\/Black-Diamond-Therapeutics-Inc.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>CAMBRIDGE, Mass., Nov. 12, 2026 (GLOBE NEWSWIRE) &#8212; Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, including silevertinib, a potential best-in-class brain-penetrant epidermal growth factor receptor (EGFR) inhibitor, today announced its participation in upcoming investor conferences. Presentation details with President and Chief Executive Officer, Mark Velleca, M.D., Ph.D., are as follows: Jefferies Global Healthcare Conference in London presentation at 8:30am GMT \/ 3:30am ET on Thursday, November 19, 2026 9th Annual Evercore ISI Healthcare Conference presentation at 10:25am ET on Tuesday, December 1, 2026 Piper Sandler 38th Annual Healthcare Conference presentation at 12:00pm ET on Wednesday, December 2, 2026 Webcasts will be available at the &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/black-diamond-therapeutics-to-participate-in-upcoming-investor-conferences-5\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Black Diamond Therapeutics to Participate in Upcoming Investor Conferences&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-1020576","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Black Diamond Therapeutics to Participate in Upcoming Investor Conferences - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/black-diamond-therapeutics-to-participate-in-upcoming-investor-conferences-5\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Black Diamond Therapeutics to Participate in Upcoming Investor Conferences - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"CAMBRIDGE, Mass., Nov. 12, 2026 (GLOBE NEWSWIRE) &#8212; Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, including silevertinib, a potential best-in-class brain-penetrant epidermal growth factor receptor (EGFR) inhibitor, today announced its participation in upcoming investor conferences. Presentation details with President and Chief Executive Officer, Mark Velleca, M.D., Ph.D., are as follows: Jefferies Global Healthcare Conference in London presentation at 8:30am GMT \/ 3:30am ET on Thursday, November 19, 2026 9th Annual Evercore ISI Healthcare Conference presentation at 10:25am ET on Tuesday, December 1, 2026 Piper Sandler 38th Annual Healthcare Conference presentation at 12:00pm ET on Wednesday, December 2, 2026 Webcasts will be available at the &hellip; Continue reading &quot;Black Diamond Therapeutics to Participate in Upcoming Investor Conferences&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/black-diamond-therapeutics-to-participate-in-upcoming-investor-conferences-5\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-11-12T21:05:04+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3NjAwMiM3OTYxNTMzIzIxOTAwNTg=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/black-diamond-therapeutics-to-participate-in-upcoming-investor-conferences-5\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/black-diamond-therapeutics-to-participate-in-upcoming-investor-conferences-5\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Black Diamond Therapeutics to Participate in Upcoming Investor Conferences\",\"datePublished\":\"2026-11-12T21:05:04+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/black-diamond-therapeutics-to-participate-in-upcoming-investor-conferences-5\\\/\"},\"wordCount\":354,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/black-diamond-therapeutics-to-participate-in-upcoming-investor-conferences-5\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg3NjAwMiM3OTYxNTMzIzIxOTAwNTg=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/black-diamond-therapeutics-to-participate-in-upcoming-investor-conferences-5\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/black-diamond-therapeutics-to-participate-in-upcoming-investor-conferences-5\\\/\",\"name\":\"Black Diamond Therapeutics to Participate in Upcoming Investor Conferences - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/black-diamond-therapeutics-to-participate-in-upcoming-investor-conferences-5\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/black-diamond-therapeutics-to-participate-in-upcoming-investor-conferences-5\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg3NjAwMiM3OTYxNTMzIzIxOTAwNTg=\",\"datePublished\":\"2026-11-12T21:05:04+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/black-diamond-therapeutics-to-participate-in-upcoming-investor-conferences-5\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/black-diamond-therapeutics-to-participate-in-upcoming-investor-conferences-5\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/black-diamond-therapeutics-to-participate-in-upcoming-investor-conferences-5\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg3NjAwMiM3OTYxNTMzIzIxOTAwNTg=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg3NjAwMiM3OTYxNTMzIzIxOTAwNTg=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/black-diamond-therapeutics-to-participate-in-upcoming-investor-conferences-5\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Black Diamond Therapeutics to Participate in Upcoming Investor Conferences\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Black Diamond Therapeutics to Participate in Upcoming Investor Conferences - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/black-diamond-therapeutics-to-participate-in-upcoming-investor-conferences-5\/","og_locale":"en_US","og_type":"article","og_title":"Black Diamond Therapeutics to Participate in Upcoming Investor Conferences - Market Newsdesk","og_description":"CAMBRIDGE, Mass., Nov. 12, 2026 (GLOBE NEWSWIRE) &#8212; Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, including silevertinib, a potential best-in-class brain-penetrant epidermal growth factor receptor (EGFR) inhibitor, today announced its participation in upcoming investor conferences. Presentation details with President and Chief Executive Officer, Mark Velleca, M.D., Ph.D., are as follows: Jefferies Global Healthcare Conference in London presentation at 8:30am GMT \/ 3:30am ET on Thursday, November 19, 2026 9th Annual Evercore ISI Healthcare Conference presentation at 10:25am ET on Tuesday, December 1, 2026 Piper Sandler 38th Annual Healthcare Conference presentation at 12:00pm ET on Wednesday, December 2, 2026 Webcasts will be available at the &hellip; Continue reading \"Black Diamond Therapeutics to Participate in Upcoming Investor Conferences\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/black-diamond-therapeutics-to-participate-in-upcoming-investor-conferences-5\/","og_site_name":"Market Newsdesk","article_published_time":"2026-11-12T21:05:04+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3NjAwMiM3OTYxNTMzIzIxOTAwNTg=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/black-diamond-therapeutics-to-participate-in-upcoming-investor-conferences-5\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/black-diamond-therapeutics-to-participate-in-upcoming-investor-conferences-5\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Black Diamond Therapeutics to Participate in Upcoming Investor Conferences","datePublished":"2026-11-12T21:05:04+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/black-diamond-therapeutics-to-participate-in-upcoming-investor-conferences-5\/"},"wordCount":354,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/black-diamond-therapeutics-to-participate-in-upcoming-investor-conferences-5\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3NjAwMiM3OTYxNTMzIzIxOTAwNTg=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/black-diamond-therapeutics-to-participate-in-upcoming-investor-conferences-5\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/black-diamond-therapeutics-to-participate-in-upcoming-investor-conferences-5\/","name":"Black Diamond Therapeutics to Participate in Upcoming Investor Conferences - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/black-diamond-therapeutics-to-participate-in-upcoming-investor-conferences-5\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/black-diamond-therapeutics-to-participate-in-upcoming-investor-conferences-5\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3NjAwMiM3OTYxNTMzIzIxOTAwNTg=","datePublished":"2026-11-12T21:05:04+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/black-diamond-therapeutics-to-participate-in-upcoming-investor-conferences-5\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/black-diamond-therapeutics-to-participate-in-upcoming-investor-conferences-5\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/black-diamond-therapeutics-to-participate-in-upcoming-investor-conferences-5\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3NjAwMiM3OTYxNTMzIzIxOTAwNTg=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3NjAwMiM3OTYxNTMzIzIxOTAwNTg="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/black-diamond-therapeutics-to-participate-in-upcoming-investor-conferences-5\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Black Diamond Therapeutics to Participate in Upcoming Investor Conferences"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1020576","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=1020576"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1020576\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=1020576"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=1020576"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=1020576"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}